Local Nasal Specific Immunotherapy for Allergic Rhinitis
Tóm tắt
The possibility of producing local hyposensitization by administering allergens via mucosal routes was envisaged at the beginning of 1900, and local nasal immunotherapy has been extensively studied since the 1970s. Presently, there are 21 randomized controlled trials being conducted with the most common allergens, consistently showing the clinical efficacy of local nasal immunotherapy for rhinitis. Other advantages are that it has an optimal safety profile and can be self-administered at home by the patient. Moreover, there are several data from animal models and from humans that confirm the immunomodulatory effect of intranasally administered antigens. On the other hand, local nasal immunotherapy seems to be effective only on rhinitis symptoms and requires a particular technique of administration. For these reasons, its clinical use is progressively declining in favour of the sublingual route although nasal immunotherapy is validated in official documents and remains a viable alternative to injection.
Tài liệu tham khảo
Noon L: Prophylactic inoculation against hay fever. Lancet. 1911, i: 1572-3. 10.1016/S0140-6736(00)78276-6.
Black JH: The oral administration of pollen. J Lab Clin Med. 1927, 12: 1156-
Black JH: The oral administration of pollen: clinical report. J Lab Clin Med. 1928, 13: 709-
Herxeimer H: Bronchial hypersensitization and hyposensitization in man. Int Arch Allergy Appl Immunol. 1951, 40: 40-57. 10.1159/000227899.
Herxeimer H, Prior EN: Further observations in induced asthma and bronchial hyposensitization. Int Arch Allergy Appl Immunol. 1952, 3: 159-61.
Scadding K, Brostoff J: Low dose sublingual therapy in patients with allergic rhinitis due to dust mite. Clin Allergy. 1986, 16: 483-91. 10.1111/j.1365-2222.1986.tb01983.x.
Committee on the Safety of Medicines: CSM update. Desensitizing vaccines. Br Med J. 1986, 293: 948-10.1136/bmj.293.6552.948.
Metha SB, Smith JM: Nasal hyposensitization and hayfever. Clin Allergy. 1975, 5: 279-84. 10.1111/j.1365-2222.1975.tb01863.x.
Taylor G, Shivalkar PR: Local nasal desensitization in allergic rhinitis. Clin Allergy. 1972, 2: 125-6. 10.1111/j.1365-2222.1972.tb01277.x.
Bousquet J, Lockey R, Malling HJ: Allergen immunotherapy: therapeutic vaccines for allergic diseases. World Health Organization position paper. Allergy. 1998, 53 Suppl
Malling HJ, Abreu-Nogueira J, Alvarez-Cuesta E: EAACI position paper on local immunotherapy. Allergy. 1998, 53: 933-44. 10.1111/j.1398-9995.1998.tb03793.x.
Bousquet J, Van Cauwenberge P: Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol. 2001, 108: S83-5. 10.1067/mai.2001.118891.
Johansson SG, Deuschl H, Zetterstrom O: Use of glutaraldehyde-modified timothy grass pollen extract in nasal hyposensitization of hay fever. Int Arch Allergy Appl Immunol. 1979, 60: 447-60. 10.1159/000232376.
Nickelsen JA, Goldstein S, Mueller U: Local intranasal immunotherapy for ragweed allergic rhinitis: clinical response. J Allergy Clin Immunol. 1981, 68: 33-40. 10.1016/0091-6749(81)90120-2.
Welsh PW, Zimmermann EM, Yunginger JW: Preseasonal intranasal immunotherapy with nebulized short ragweed extract. J Allergy Clin Immunol. 1981, 67: 237-42. 10.1016/0091-6749(81)90067-1.
Schumacher MJ, Pain MC: Intranasal immunotherapy and polymerized grass pollen allergens. Allergy. 1982, 37: 241-8. 10.1111/j.1398-9995.1982.tb01906.x.
Georgitis JW, Reisman RE, Clayton WF: Local nasal immunotherapy for grass allergic rhinitis. J Allergy Clin Immunol. 1983, 71: 71-6. 10.1016/0091-6749(83)90549-3.
Georgitis JW, Clayton WF, Wypich JI: Further evaluation of local nasal immunotherapy with aqueous and allergoid grass extract. J Allergy Clin Immunol. 1984, 74: 694-700. 10.1016/0091-6749(84)90232-X.
Andri L, Senna GE, Betteli C: Local nasal immunotherapy in allergic rhinitis to Parietaria. Allergy. 1992, 47: 318-23. 10.1111/j.1398-9995.1992.tb02061.x.
Andri L, Senna GE, Betteli C: Local nasal immunotherapy for Dermatophagoides-induced rhinitis: efficacy of a powder extract. J Allergy Clin Immunology. 1993, 91: 587-96. 10.1016/0091-6749(93)90211-W.
Passalacqua G, Albano M, Ruffoni S: Local nasal immunotherapy to Parietaria : evidence of reduction of allergic inflammation. Am J Respir Crit Care Med. 1995, 152: 461-6.
D'Amato G, Lobefalo G, Liccardi G, Cazzola M: A double blind placebo controlled trial of local nasal immunotherapy in allergic rhinitis to Parietaria pollen. Clin Exp Allergy. 1995, 25: 141-8. 10.1111/j.1365-2222.1995.tb01019.x.
Andri L, Senna GE, Andri G: Local nasal immunotherapy for birch allergic rhinitis with extract in powder form. Clin Exp Allergy. 1995, 25: 1092-9. 10.1111/j.1365-2222.1995.tb03256.x.
Fanales-Belasio E, Ciofalo A, Zambetti G: Intranasal immunotherapy with Dermatophagoides extract: in vivo and in vitro results of a double-blind placebo-controlled trial. Rhinology. 1995, 33: 126-31.
Andri L, Senna GE, Betteli C: Local nasal immunotherapy with extract in powder form is effective and safe in grass pollen rhinitis. Adouble blind study on 32 patients. J Allergy Clin Immunol. 1996, 97: 37-41.
Cirla A, Sforza N, Roffi GP: Preseasonal intranasal immunotherapy in birch-alder rhinitis. Adouble blind study. Allergy. 1996, 51: 299-305.
Bardare M, Zaini C, Novembre E, Vierucci A: Local nasal immunotherapy with a powder extract for grass pollen rhinitis in pediatric ages. A controlled study. J Invest Allergol Clin Immunol. 1996, 97: 34-41.
Gaglani B, Borish L, Bartelson BL: Nasal immunotherapy in weed-induced allergic rhinitis. Ann Allergy Asthma Immunol. 1997, 79: 259-65. 10.1016/S1081-1206(10)63012-8.
Bertoni M, Cosmi F, Bianchi I, Di Berardino L: Clinical efficacy and tolerability of a steady dosage schedule of local nasal immunotherapy. Results of preseasonal treatment in grass pollen rhinitis. Ann Allergy Asthma Immunol. 1999, 82: 47-51. 10.1016/S1081-1206(10)62659-2.
Motta G, Passali D, De Vincentiis I: A multicenter trial of specific local nasal immunotherapy. Laryngoscope. 2000, 110: 132-9. 10.1097/00005537-200001000-00024.
Pocobelli D, Del Bono A, Venuti L: Nasal immunotherapy at constant dosage: a double blind placebo controlled study in grass allergic rhinoconjunctivitis. J Invest Allergol Clin Immunol. 2001, 11: 79-88.
Marcucci F, Sensi LG, Caffarelli C: Low-dose local nasal immunotherapy in children with perennial allergic rhinitis due to Dermatophagoides. Allergy. 2002, 57: 23-8. 10.1034/j.1398-9995.2002.13149.x.
Passali D, Bellussi L, Passali GC, Passali FM: Nasal immunotherapy is effective in the treatment of rhinitis due to mite allergy. A double-blind, placebo-controlled study with rhinological evaluation. Int J Immunopathol Pharmacol. 2002, 15: 141-7.
Olivieri M, Mohaddes Zadeh MR, Talamini G: Local nasal immunotherapy and bronchial hyperreactivity in seasonal allergic rhinitis: an observational pilot study. J Investig Allergol Clin Immunol. 2000, 10: 300-4.
Passalacqua G, Albano M, Pronzato C: Nasal immunotherapy to Parietaria : long term follow up of a double blind study. Clin Exp Allergy. 1997, 27: 904-8. 10.1111/j.1365-2222.1997.tb01231.x.
Andri L, Falagiani P: Symptomatic relief after grass nasal immunotherapy: lasting efficacy after 4-5 years. J Investig Allergol Clin Immunol. 2003, 13: 228-31.
Bjorksten B: Local immunotherapy is not documented for clinical use. Allergy. 1994, 49: 299-301. 10.1111/j.1398-9995.1994.tb02271.x.
Senna GE, Andri L, Dama A: Local nasal immunotherapy: efficacy and tolerability of two different administration schedules in grass pollen rhinitis. Allergol Immunopathol (Madr). 2000, 28: 238-42.
Taylor G, Shivalkar E: Changes in nasal airways resistance on antigenic challenge in allergic rhinitis. Clin Allergy. 1971, 1: 63-73. 10.1111/j.1365-2222.1971.tb02448.x.
Koh YY, Lim HS, Min KU, Min YG: Airways of allergic rhinitics are 'primed' to repeated allergen inhalation challenge. Clin Exp Allergy. 1994, 24: 337-46. 10.1111/j.1365-2222.1994.tb00244.x.
Ciprandi G, Ricca V, Landi M: Allergen specific nasal challenge: response kinetic of clinical and inflammatory events to rechallenge. Int Arch Allergy Immunol. 1998, 115: 157-61. 10.1159/000023896.
Holt PG, Sedgwick JD: Suppression of IgE response following antigen inhalation: a natural homeostatic mechanism which limits sensitizations to aeroallergens. Immunol Today. 1987, 8: 14-5. 10.1016/0167-5699(87)90825-5.
Holt PG, Reid M, Britten D: Suppression of IgE responses by passive antigen inhalation: dissociation of local and systemic immunity. Cell Immunol. 1987, 104: 434-9. 10.1016/0008-8749(87)90045-1.
Tsitoure DC, DeKruyff RH, Lamb JR, Umetsu DT: Intranasal exposure to antigen induces immunological tolerance mediated by functionally disabled CD4+ T cells. J Immunol. 1999, 163: 2592-600.
Barbey C, Donatelli-Dufour N, Batard P: Intranasal treatment with ovalbumin but not the major T cell epitope ovalbumin 323-339 generates interleukin-10 secreting T cells and results in the induction of allergen systemic tolerance. Clin Exp Allergy. 2004, 34: 654-62. 10.1111/j.1365-2222.2004.1929.x.
Hall G, Houghton CG: Suppression of allergen reactive Th2 mediated responses and pulmonary eosinophilia by intranasal administration of an immunodominant peptide is linked to IL-10 production. Vaccine. 2003, 21: 549-61. 10.1016/S0264-410X(02)00394-8.
Till SJ, Francis JN, Nouri-Aria K, Durham SR: Mechanisms of immunotherapy. J Allergy Clin Immunol. 2004, 113: 1025-34. 10.1016/j.jaci.2004.03.024.
Robinson DS, Larche M, Durham SR: Tregs and allergic disease. J Clin Invest. 2004, 114: 1389-97.
Giannarini L, Maggi E: Decrease of allergen specific T cell response induced by nasal immunotherapy. Clin Exp Allergy. 1998, 28: 404-12. 10.1046/j.1365-2222.1998.00265.x.
Mistrello G, Rapisarda G, Falagiani P: Detection of IgE-binding activity in serum after intranasal treatment of normal rabbits with P. judaica extracts. Allergy. 1991, 46: 52-5. 10.1111/j.1398-9995.1991.tb00543.x.
Buckle FB, Cohen AB: Nasal mucosal hyper-permeability to macromolecules in atopic rhinitis and extrinsic asthma. J Allergy Clin Immunol. 1975, 55: 213-21. 10.1016/0091-6749(75)90139-6.
Falagiani P, Mistrello G: Pharmacokinetics of allergens after local administration. Allergy. 1997, 52: 17-21. 10.1111/j.1398-9995.1997.tb04799.x.
Bagnasco M, Mariani G, Passalacqua G: Absorption and distribution kinetics of the major Parietaria allergen administered by noninjectable routes to healthy human beings. J Allergy Clin Immunol. 1997, 100: 122-9. 10.1016/S0091-6749(97)70203-3.
Bagnasco M, Passalacqua G, Villa G: Pharmacokinetics of an allergen and a monomeric allergoid for oromucosal immunotherapy in allergic volunteers. Clin Exp Allergy. 2001, 31: 54-60. 10.1046/j.1365-2222.2001.00999.x.
Passalacqua G, Altrinetti V, Mariani G: Pharmacokinetics of radiolabelled Par j 1 administered intranasally to allergic and healthy subjects. Clin Exp Allergy. 2005, 35: 880-3. 10.1111/j.1365-2222.2005.2226.x.